Patient in Sarepta gene therapy trial develops serious illness; shares plunge

REUTERS: Shares of Sarepta Therapeutics Inc plunged 12per cent after a notice from the U.S. health agency showed a patient in an ongoing study of the company's gene therapy for Duchenne muscular dystrophy was reported to have developed a serious illness.

The incident, which occurred in February, involved a seven-year-old boy who developed rhabdomyolysis, a serious condition that can lead to complications such as kidney failure.Sarepta did not immediately respond to Reuters' request for comment.

Health Health Latest News, Health Health Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

Fans praise 'strong warrior' Selma Blair for new bikini photo during MS treatment“For the thousands who have no voice, no way of publicizing their chronic, silent illnesses, you give a face to.'
Source: YahooSG - 🏆 3. / 71 Read more »

Drug assistance programs offer little charity to uninsured(Reuters Health) - Many patients who receive assistance from charities set up to defray prescription drugs costs may already have insurance that ...
Source: ChannelNewsAsia - 🏆 6. / 66 Read more »